## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

	FORM 8-K	
	CURRENT REPORT	
	Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934	
Date of R	eport (Date of earliest event reported): Mar	ch 11, 2021
(Exa	Atreca, Inc.	arter)
Delaware (State or Other Jurisdiction of Incorporation)	001-38935 (Commission File Number)	27-3723255 (IRS Employer Identification No.)
450 East Jamie Court South San Francisco, California (Address of Principal Executive Offices)		94080 (Zip Code)
(Regi	(650) 595-2595 strant's Telephone Number, Including Area	Code)
Check the appropriate box below if the Form 8-K is following provisions (see General Instructions A.2. be		ne filing obligation of the registrant under any of the
☐ Written communications pursuant to Rule 425	under the Securities Act (17 CFR 230.425)	
☐ Soliciting material pursuant to Rule 14a-12 und	ler the Exchange Act (17 CFR 240.14a-12)	
☐ Pre-commencement communications pursuant	to Rule 14d-2(b) under the Exchange Act (17 (	CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant	to Rule 13e-4(c) under the Exchange Act (17 C	CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the S	Securities Exchange Act of 1934:	
Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class A Common Stock, \$0.0001 par value per share	BCEL	The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an chapter) or Rule 12b-2 of the Securities Exchange Act		e 405 of the Securities Act of 1933 (§230.405 of this
Emerging growth company $oximes$		
If an emerging growth company, indicate by check m or revised financial accounting standards provided pur		extended transition period for complying with any new

## Item 8.01 Other Events.

On March 11, 2021, Atreca, Inc. (the "Company") announced that Tito A. Serafini, Ph.D., a founder, a director, and the Chief Strategy Officer of the Company, will lead business development activities at the Company, effective March 13, 2021. Lisa L. Decker, Ph.D., Chief Business Officer of the Company, will be resigning to pursue a new business opportunity, effective March 12, 2021. Dr. Decker's resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies, or practices. The Company thanks Dr. Decker for her contributions and wishes her well in her new role.

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Atreca, Inc.

Dated: March 11, 2021 By: /s/ Herbert Cross

Herbert Cross Chief Financial Officer